Inside news from AMLN

Mole - you are a clown that spits out pointless nonsense

 

Hey, if you were stuck in this fucking hole, with everyone expecting you to be some kind of swami, eating roots, worms and fucking bugs, you'd be pissed off too.

Mole

 

mole where the hell are you? what's going on???

 

The mole and the the other newly promoted VP's have employed their golden parachutes and left the building.

 

Merck, Sanofi also made initial bids last week-sources

* All first-round bids came above $25 per share-sources

* Second-round bids expected in next several weeks

By Ben Hirschler and Toni Clarke

LONDON/BOSTON, June 1 (Reuters) — AstraZeneca Plc and Bristol-Myers Squibb Co are among several pharmaceutical giants that have submitted initial bids for Amylin Pharmaceuticals Inc, the diabetes drugmaker that is exploring a sale, according to people familiar with the matter.

Other companies that also made initial bids for Amylin last week include Merck & Co and Sanofi, the sources said.

Amylin put itself up for sale after spurning a $3.5 billion takeover bid from Bristol earlier this year, under pressure from activist investor Carl Icahn. It is expected to seek second-round bids in the next several weeks, the sources said.

Two of the sources said all the parties made bids of at least $25 a share, valuing Amylin at more than $4 billion. It was not clear whether any other drugmakers in addition to the four companies also submitted bids.

Shares of Amylin are trading at about $26 on Nasdaq, valuing the company at more than $4.2 billion.

Representatives for Amylin, Bristol-Myers, AstraZeneca, Merck and Sanofi all declined to comment.

Amylin, which makes diabetes drugs Byetta and Bydureon, started reaching out to potential buyers in April after hiring Credit Suisse and Goldman Sachs as its financial advisers and Skadden Arps as its legal adviser, sources told Reuters previously.

Big pharmaceutical companies, flush with cash and easy access to debt, have been making aggressive bids for promising biotech firms and other targets as they look to find new products and replenish their pipelines.

But often they find the targets, whose shares are sometimes depressed, holding out for a better price.

Other such bids in the healthcare sector in recent months include an aborted $6.8 billion hostile takeover attempt by Swiss drugmaker Roche Holding AG for genetic specialist Illumina Inc, and a bid by GlaxoSmithKline Plc to buy long-time partner Human Genome Sciences Inc for about $2.6 billion.

Amylin has been considered a possible takeover target for some time, with the diabetes market being one of the fastest-growing due to rising rates of obesity.

The disease affects more than 300 million people worldwide, including nearly 26 million Americans. Diabetics run a high risk of heart disease, stroke, kidney failure, blindness and limb loss.

Pressure on Amylin increased after news of the failed Bristol-Myers bid leaked and prompted Icahn to turn his sights on the company. Icahn, whose 8.94 percent stake has made him Amylin’s third-largest shareholder, has called for a sale.

The opportunity for bidders to make their move on Amylin also got a boost when Amylin ended a nearly decade-long partnership with Eli Lilly and Co in November last year.

Amylin and Lilly introduced Byetta in 2005. Bydureon, a longer-acting version, was approved recently. The dissolution of the partnership with Lilly made Amylin responsible for selling its products in the United States, while leaving the company to find a new partner outside the country.

Buying Amylin would complement the diabetes portfolios of many large drug companies, according to analysts, although acquirers will be wary of the increasingly competitive landscape for so-called GLP-1 drugs like Byetta and Bydureon, several more of which could hit the market in the next couple of years.

Merging the Amylin operation with a large business would create opportunities to rationalize marketing costs, by reducing the number of U.S. sales representatives, and pushing Amylin’s products through a larger international sales force would increase their commercial reach.

Leerink Swann analyst Seamus Fernandez said AstraZeneca’s European presence might give it an advantage relative to Bristol, but Sanofi and Merck could be better placed to fully capitalize on Amylin’s diabetes business.

Reuters, 06/01/12 13:43

 

We are going to be bought by someone.

Mole

 

News from inside Amylin...the mole lives.

Offers are in and being reviewed by bankers and financiers. Best and final offers will be asked for per Goldman employee within the week. Goldman's people are calling the shots on how the communication and leaks will take place going forward.

Several of the offers restrict Amylin to publicly announce the offer or terms change. This is a weak attempt to prevent a racheting up of the bids through the media. One offer is below current share price. That company is out. Other's are higher, although the exec's are extremely tight lipped about the discussions. Trying to pull information, but everyone is very quiet about the terms and offers.

Dan and team are discussing how happy they are that the board approved increases in the financial value of their packages in the last quarter. All stand to make in the hundreds of thousands to millions. Dan will pocket over $10M. Everyone is very happy and keeping their game faces on. Vince was given direction to keep communication very high to the field through Jake. They have been told to float the option of keeping people's hopes up that the field force might stay once the purchase happens. Heard a Goldman manager say in the hall, "there is no way in hell that any company will keep this sales force"...

Executives were told to stay positive, keep the business moving, and show no celebratory emotion in front of employees.

Dan has already informally met with board members of different companies to line up his next move.

Mole

 

While "the mole" might sound credible, any dimwit can write this drivel. This forum already knows Amylin execs are drooling over how much money they will take away from this deal. Management of this company does not give a shit about patients or employees. It is and always has been about them all the time.

We only care about two pieces of concrete information:
How much is this shithole selling for?
Which crappy company is the winner?

We will make some predications to prove your BS inside "information" could be guessed by any idiot.

Execs gone within 3 months, golden parachute packs stuffed with cash. 90% of employees outside of Ohio will be gone before the end of the year, including sales. Projects moving forward to keep up the appearance of business as usual, even though everyone knows this shit shack stinks to high heaven. More apathy, stealing and lying until the doors are closed forever.

 

Amen brother. Must be nice for all the people getting promotions to director or above to get that year's worth of severance. Kiss ass much jerk offs? Anyone who sees that will know that you either screwed, blew or blackmailed your boss for it, so wear that shiny new title with pride while it lasts. The expensive, USELESS ones are the first ones to go.

 

"All stand to make in the hundreds of thousands to millions. Dan will pocket over $10M."

sorry mole but this was a dead give away that you know nothing. if you think any of the executives stand to make "hundreds of thousands" and that Dan will only pocket $10M you are completely uninformed. All the Execs at the Sr VP & C level will be making millions and Dan will be making 10s of millions. most of the Sr Directions and VPs will also be making millions so you're either full of it or dropped a decimal point along the way

 

Mole predicted 5.5b for the company in Apl. Amln sells for 5.3b. Pretty close.